This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

PET Imaging and Olanzapine Treatment in Borderline Personality Disorder

This study has been completed.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT00275301
First received: January 10, 2006
Last updated: April 17, 2017
Last verified: April 2017
January 10, 2006
April 17, 2017
December 2005
April 2008   (Final data collection date for primary outcome measure)
Change in Brain Metabolism From Baseline to Eight Weeks as Seen in PET Scan [ Time Frame: Baseline to 8 weeks ]
The primary aim of this imaging study was to examine the effect of olanzapine on brain metabolism over the eight weeks of administration. To compare the baseline PET scan to the endpoint scan,
The primary objective of this proposed study will be to compare the baseline PET scan to the endpoint scan in 15 BPD patients who have been treated with olanzapine. The comparison of the scans will be done through a statistical image analysis.
Complete list of historical versions of study NCT00275301 on ClinicalTrials.gov Archive Site
Not Provided
A secondary objective is to use a normal database to compare the baseline PET scan of the 15 patients in a medication free state to normal subjects. The advantage of this strategy is the ability to closely match subjects by gender and age.
Not Provided
Not Provided
 
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
Brain Correlates of Olanzapine Treatment Response in BPD
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.

The primary objective of this proposed study will be to compare the baseline PET scan to the endpoint scan in 15 BPD patients who have been treated with olanzapine. The comparison of the scans will be done through a statistical image analysis, using a pixel-by-pixel group mean subtraction strategy with appropriate correction for multiple comparisons. In an exploratory fashion we will compare frontal and temporal regions of interest to address hypotheses of which areas of the brain might show changes with olanzapine treatment.

A secondary objective is to use a normal database to compare the baseline PET scan of the 15 patients in a medication free state to normal subjects. The advantage of this strategy is the ability to closely match subjects by gender and age. As noted earlier, Dr. Pardo has data on 35 control subjects studied on the same scanner we plan to use for this study.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Borderline Personality Disorder
Drug: olanzapine
Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
Other Name: Zyprexa
Experimental: Open-label Olanzapine.
Open-label Olanzapine.
Intervention: Drug: olanzapine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
19
December 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 18-45 years
  2. Diagnosis: borderline personality disorder by DSM-IV criteria
  3. Gender: Female
  4. May have history of substance use and other Axis II disorders

Exclusion Criteria:

  1. Axis I diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder during the subject's lifetime. No current major depression or PTSD.
  2. Treatment with psychotropic medication in the previous month.
  3. Medical disorder that would influence outcome of the study - e.g. epilepsy, thyroid disease, HIV, etc.
  4. Medical disorder that would not allow use of olanzapine
  5. Active substance abuse or dependence
  6. Previous adverse reaction to olanzapine
  7. Females whom are pregnant or nursing
Sexes Eligible for Study: Female
18 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00275301
0506M70791
No
Not Provided
Not Provided
Not Provided
University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
Eli Lilly and Company
Principal Investigator: S. Charles Schulz, MD University of Minnesota - Clinical and Translational Science Institute
University of Minnesota - Clinical and Translational Science Institute
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP